FIG 8.

Pre-F-GCN4t antigenicity. (A) Pre-F-GCN4t or Post-F-XC at decreasing concentrations was used to inhibit the neutralizing activity of a convalescent-phase serum pool (left) or palivizumab (right) in a neutralization inhibition assay. (B) Biacore sensorgrams of Pre-F-GCN4t injected at different concentrations onto captured palivizumab. Association and dissociation constants (ka, kd, and KD) are indicated in the table. (C) Binding of the D25 antibody to Pre-F-GCN4t and Post-F-XC. D25 at increasing concentrations was used to bind immobilized Pre-F-GCN4t or Post-F-XC in a microtiter plate. D25 binding was revealed by peroxidase-labeled anti-human IgG Fc antibody followed by a peroxidase substrate. OD, optical density.